Think of it as a tool to support a healthier way of living, not a magic bullet
Because glucagon-receptor agonism could theoretically raise glucose, the phase 2 program specifically examined participants with type 2 diabetes and found that retatrutide lowered HbA1c rather than raising it evidence that the molecules GLP-1 and GIP activity more than offsets any glucagon-driven glucose elevation
Pricing may vary based on dosage, medical evaluation, and provider recommendations
Therapeutic approaches aim primarily at symptom reduction and prevention of disease progression
Abrahamsson, N
M., Shab-Bidar, S., Kord-Varkaneh, H., Khorshidi, M., & Djafarian, K